Table 8.

US clinical trials using propranolol as cancer treatment.

β-AR blockade	NCT Number	Title	Status	Study Results	Conditions	Interventions	Phases	Enrollment
1	NCT01847001	Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy	Completed	Propranolol + Neoadjuvant Chemotherapy SAE 10%	Locally Advanced Malignant Neoplasm|Breast Cancer	Drug: Propranolol|Other: DOT imaging|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Procedure: Surgery|Drug: Premedication|Drug: Anti-nausea therapy|Drug: Pegfilgrastim	Phase 2	10
2	NCT01308944	Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients	Completed	No Results Available	Invasive Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer	Drug: Propranolol	Phase 1	24
3	NCT02165683	Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans	Completed	No Results Available	Pediatric Cancer	Drug: Propranolol	Phase 1	10
4	NCT01902966	Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)	Terminated	dose escalation 40 mg by mouth twice a day, SAE 20%	Cervical Cancer	Drug: Propranolol|Behavioral: Diary|Behavioral: Relaxation Audio Recording|Behavioral: Questionnaires	Not Applicable	6
5	NCT04848519	Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer	Recruiting	No Results Available	Recurrent or Metastatic Urothelial Cancer	Drug: Pembrolizumab|Drug: Propranolol Hydrochloride	Phase 2	25
6	NCT03152786	Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery	Suspended	No Results Available	Prostate Carcinoma	Other: Laboratory Biomarker Analysis|Drug: Propranolol Hydrochloride|Other: Questionnaire Administration|Other: Survey Administration	Phase 2	50
7	NCT05651594	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Recruiting	No Results Available	Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Procedure: Biopsy|Procedure: Biospecimen Collection|Procedure: Computed Tomography|Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Biological: Pembrolizumab|Drug: Propranolol Hydrochloride|Other: Questionnaire Administration	Phase 2	40
8	NCT01504126	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Completed	No Results Available	Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Drug: Chemotherapy|Drug: Propranolol Hydrochloride|Other: Quality-of-Life Assessment|Procedure: Therapeutic Conventional Surgery	Early Phase 1	32
9	NCT04682158	Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma	Recruiting	No Results Available	Esophageal Adenocarcinoma	Drug: Carboplatin|Radiation: 3 Dimensional Conformal Radiation Therapy|Drug: Propranolol|Radiation: Intensity Modulated Radiation Therapy|Drug: Paclitaxel	Phase 2	60
10	NCT03384836	Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	Recruiting	No Results Available	Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7	Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Propranolol Hydrochloride	Phase 1|Phase 2	47
11	NCT00967226	Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas	Terminated	Propranolol SAE 1/11 (9.09%)	Hemangioma of Infancy	Drug: propranolol|Drug: Prednisolone	Phase 2	19
12	NCT05312255	Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma	Recruiting	No Results Available	Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Smoldering Plasma Cell Myeloma	Behavioral: Behavioral Intervention|Drug: Beta-Adrenergic Antagonist|Drug: Propranolol|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Other: Resistance Training|Other: Short-Term Fasting	Not Applicable	150
13	NCT01074437	Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)	Terminated	Has Results	Hemangioma	Drug: Prednisolone (Corticosteroid)|Drug: Propranolol|Drug: Placebo	Phase 2	9
14	NCT05479123	Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas	Recruiting	No Results Available	Infantile Hemangioma	Drug: Propranolol three times a day|Drug: Propranolol twice a day|Drug: Timolol	Phase 4	174
15	NCT01056341	Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy	Completed	Propranolol 3mg/kg/d 6 Months, 60.4% resolution. SAE 4.95% for Propranolol 3mg/kg/day for 6 months	Infantile Hemangioma	Drug: Propranolol|Drug: Placebo	Phase 2|Phase 3	512
16	NCT01265576	Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)	Unknown status	No Results Available	HCC	Drug: Sorafenib|Drug: VT-122 (propranolol plus etodolac)|Drug: Placebo	Phase 2	20